Elia Neninger

1.1k total citations
34 papers, 661 citations indexed

About

Elia Neninger is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Elia Neninger has authored 34 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Elia Neninger's work include Immunotherapy and Immune Responses (16 papers), Glycosylation and Glycoproteins Research (13 papers) and Lung Cancer Research Studies (10 papers). Elia Neninger is often cited by papers focused on Immunotherapy and Immune Responses (16 papers), Glycosylation and Glycoproteins Research (13 papers) and Lung Cancer Research Studies (10 papers). Elia Neninger collaborates with scholars based in Cuba, Belgium and United Kingdom. Elia Neninger's co-authors include Tania Crombet, Agustín Lage, Beatriz García Verdecia, Carmen Viada, Gisela González, Rolando Pérez, Zaima Mazorra, Mauricio Catalá, Ana de la Torre and I. Leonard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Elia Neninger

30 papers receiving 647 citations

Peers

Countries citing papers authored by Elia Neninger

Since Specialization

Citations

This map shows the geographic impact of Elia Neninger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elia Neninger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elia Neninger more than expected).

Fields of papers citing papers by Elia Neninger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elia Neninger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elia Neninger. The network helps show where Elia Neninger may publish in the future.

Co-authorship network of co-authors of Elia Neninger

This figure shows the co-authorship network connecting the top 25 collaborators of Elia Neninger. A scholar is included among the top collaborators of Elia Neninger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elia Neninger. Elia Neninger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer 2021 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), (unknown), Patricia Lorenzo-Luaces, Elia Neninger, (unknown), (unknown), Mauricio Catalá, Nuris Ledón, (unknown), (unknown), Beatriz García Verdecia, Tania Crombet, Zaima Mazorra, Danay Saavedra, Agustín Lage	8
2	High Levels of Serum EGF Concentration Predict Response to Cimavax-EGF Treatment in Advanced NSCLC 2020 ·(unknown), (unknown), Elia Neninger, Tania Crombet	0
3	P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC 2019 ·Journal of Thoracic Oncology ·Elia Neninger, (unknown), (unknown), M. Hernández, (unknown), Christie del Castillo-Hegyi, (unknown), Bruno J. Gonzalez	1
4	Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer 2018 ·Seminars in Oncology ·Lizet Sánchez, Leacky Muchene, Patricia Lorenzo-Luaces, Carmen Viada, Pedro C. Rodríguez, (unknown), Tania Crombet, Elia Neninger, Ziv Shkedy, Agustín Lage	6
5	CIMAvax-EGF: Toward long-term survival of advanced NSCLC 2018 ·Seminars in Oncology ·Danay Saavedra, Elia Neninger, (unknown), Carmen Viada, Zaima Mazorra, Agustín Lage, Tania Crombet	17
6	Security 1E10 anti-idiotypic vaccine in patients with tumors of different locations 2016 ·Bionatura ·(unknown), Carmen Viada, Martha Fors, (unknown), Elia Neninger, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Amparo Macías, (unknown), Maurenis Hernández, (unknown), (unknown), (unknown)	1
7	Switch maintenance therapy with racotumomab or nimotuzumab vs docetaxel for NSCLC patients 2016 ·Annals of Oncology ·M. Hernández, Elia Neninger, Ramon A. Ortiz, (unknown), (unknown), Lorenzo Bello, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yanelys Morera Díaz, Carmen Viada, (unknown), (unknown), (unknown), (unknown), (unknown), Tania Crombet	1
8	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC 2016 ·Journal of Thoracic Oncology ·Rafael Rosell, Elia Neninger, M. Nicolson, Rudolf M. Huber, Sumitra Thongprasert, Purvish M. Parikh, E. D'Hondt	11
9	Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients 2015 ·Cancer Immunology Immunotherapy ·Danay Saavedra, Beatriz García Verdecia, Patricia Lorenzo-Luaces, (unknown), (unknown), (unknown), Zaima Mazorra, Tania Crombet, Elia Neninger, Agustín Lage	47
10	EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers. 2013 ·Journal of Clinical Oncology ·Tania Crombet, Elia Neninger, (unknown), Pedro C. Rodríguez, Beatriz García Verdecia, (unknown), Zaima Mazorra, Carmen Viada, (unknown), Gisela González, Agustín Lage	6
11	Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients 2011 ·PubMed ·Pedro C. Rodríguez, Elia Neninger, Beatriz García Verdecia, (unknown), Carmen Viada, (unknown), Gisela González, Agustín Lage, Enrique Montero, Tania Crombet	22
12	CIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer 2009 ·SHILAP Revista de lepidopterología ·Gisela González, Agustín Lage, Tania Crombet, (unknown), Beatriz García Verdecia, (unknown), (unknown), (unknown), Elia Neninger	4
13	Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer 2008 ·Journal of Immunotherapy ·Elia Neninger, Beatriz García Verdecia, Tania Crombet, Carmen Viada, (unknown), I. Leonard, Zaima Mazorra, (unknown), (unknown), (unknown), Gisela González, Agustín Lage	53
14	Therapeutic Vaccination with Epidermal Growth Factor (EGF) in Advanced Lung Cancer: Analysis of Pooled Data from Three Clinical Trials 2007 ·Human Vaccines ·Gisela González, Tania Crombet, Elia Neninger, Carmen Viada, Agustín Lage	55
15	Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial 2007 ·Cancer Biology & Therapy ·Elia Neninger, Rosa María Díaz, Ana de la Torre, (unknown), (unknown), Giselle Saurez, Mariano R. Gabri, Daniel F. Alonso, (unknown), (unknown), (unknown), Rolando Pérez, Ana María Vázquez	72
16	199 POSTER Efficacy evaluation of the humanized anti-EGFR MAb h-R3 (nimotuzumab) in combination with radiotherapy in the treatment of patients with unresectable squamous cell carcinomas of the head and neck 2006 ·European Journal of Cancer Supplements ·Tania Crombet, Marta Osorio, (unknown), José Alert, (unknown), J. González, Elia Neninger, (unknown), (unknown), (unknown)	1
17	Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin 2005 ·Nuclear Medicine Communications ·Leonel Torres, (unknown), (unknown), (unknown), Tania Crombet, Mayra Ramos, Elia Neninger, (unknown), (unknown), (unknown), (unknown), (unknown), Normando Iznaga-Escobar	25
18	Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer 2003 ·Journal of Immunotherapy ·Tania Crombet, Leonel Torres, Elia Neninger, Mauricio Catalá, María Emilia Solano, (unknown), Olga Torres, Normando Iznaga, (unknown), Rolando Pérez, Agustín Lage	94
19	Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy 2003 ·Annals of Oncology ·Gabriela Gonzalez, Tania Crombet, (unknown), Mauricio Catalá, Lloyd F. Alfonso, Marta Osorio, Elia Neninger, Beatriz García Verdecia, (unknown), Rolando Pérez, (unknown)	91
20	Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody against Epidermal Growth Factor Receptor 2001 ·Cancer Biotherapy and Radiopharmaceuticals ·Tania Crombet, Olga Torres, Elia Neninger, Mauricio Catalá, Nelson Rodríguez, Mayra Ramos, Eduardo Fernández, Normando Iznaga, Rolando Pérez, Agustín Lage	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact